Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semzuvolimab - United Biopharma

Next Previous
Drug Profile

Semzuvolimab - United Biopharma

Alternative Names: dB4; dB4C7 mAb; dB4C7C22-6 mAb; mAb B4; UB-421

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United Biomedical
  • Developer Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans General Hospital; United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 04 Jan 2024 Semzuvolimab is still in phase III trials for HIV-1 infections in Taiwan, China, Thailand
  • 25 Apr 2023 United Biopharma withdraws a phase III trial prior to enrolment due to project adjustment for HIV-1 infections (Monotherapy) in China (IV) (NCT03149211)
  • 01 Feb 2023 United BioPharma completes a phase II trial for HIV-1 infection (Treatment experienced, Monotherapy, Combination therapy) (NCT05056974)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top